Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential

Vasily J. Assikis, Kim Anh Do, Sijin Wen, Xuemei Wang, Jeong Hee Cho, Shawn Brisbay, Remigio Lopez, Christopher J. Logothetis, Patricia Troncoso, Christos N. Papandreou, Timothy J. McDonnell

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: We have identified a subset of patients exhibiting extended survival with metastases from androgen-independent prostate cancer of which the principal site of progression was the tumor primary. The purpose of this study was to evaluate the expression of selected biomarkers to characterize this subset of prostate cancer patients. Experimental Design: A 105 core tissue microarray was constructed from primary tamor samples from 16 patients, with matched lymph node metastases in 5 cases. Immunohistochemistry was used to evaluate selected biomarkers associated with prostate cancer progression. Standard statistical methodologies were used to compute the distribution of time to progression and overall survival associations between pairs of biomarkers. Hierarchical clustering was done between groups of biomarkers, and we devised new methods to assess homogeneity of biomarker expression. Results: The median interval from diagnosis to salvage surgery was 65 months. The profile of biomarker expression was notable for virtual absence of neuroendocrine features, high CD10, low matrix metalloproteinase (MMP)-9, high E-cadherin expression, and high membranous β-catenin. The mean proliferative index was 12.1 ± 10.1%, and the mean apoptotic index was 3.48 ± 2.22%, and there was a significant correlation between these indices. Expression of the epidermal growth factor receptor was associated with phospho-AKT and proliferative index but inversely associated with phospho-STAT3. Conclusions: The cohort of prostate cancer patients, characterized by locally aggressive disease rather than lethal metastatic progression, was associated with a distinctive biomarker signature. The biomarker profile was, in general, more consistent with low-grade prostate cancer exhibiting local growth rather than metastatic progression. Ongoing studies will establish whether this unique subset of patients can be identified prospectively.

Original languageEnglish (US)
Pages (from-to)6770-6778
Number of pages9
JournalClinical Cancer Research
Volume10
Issue number20
DOIs
StatePublished - Oct 15 2004
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Biomarkers
Neoplasm Metastasis
Catenins
Survival
Matrix Metalloproteinase 9
Cadherins
Epidermal Growth Factor Receptor
Cluster Analysis
Research Design
Lymph Nodes
Immunohistochemistry
Growth
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. / Assikis, Vasily J.; Do, Kim Anh; Wen, Sijin; Wang, Xuemei; Cho, Jeong Hee; Brisbay, Shawn; Lopez, Remigio; Logothetis, Christopher J.; Troncoso, Patricia; Papandreou, Christos N.; McDonnell, Timothy J.

In: Clinical Cancer Research, Vol. 10, No. 20, 15.10.2004, p. 6770-6778.

Research output: Contribution to journalArticle

Assikis, VJ, Do, KA, Wen, S, Wang, X, Cho, JH, Brisbay, S, Lopez, R, Logothetis, CJ, Troncoso, P, Papandreou, CN & McDonnell, TJ 2004, 'Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential', Clinical Cancer Research, vol. 10, no. 20, pp. 6770-6778. https://doi.org/10.1158/1078-0432.CCR-04-0275
Assikis, Vasily J. ; Do, Kim Anh ; Wen, Sijin ; Wang, Xuemei ; Cho, Jeong Hee ; Brisbay, Shawn ; Lopez, Remigio ; Logothetis, Christopher J. ; Troncoso, Patricia ; Papandreou, Christos N. ; McDonnell, Timothy J. / Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 20. pp. 6770-6778.
@article{b11a5d3c14a141679f43792caae9b9aa,
title = "Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential",
abstract = "Purpose: We have identified a subset of patients exhibiting extended survival with metastases from androgen-independent prostate cancer of which the principal site of progression was the tumor primary. The purpose of this study was to evaluate the expression of selected biomarkers to characterize this subset of prostate cancer patients. Experimental Design: A 105 core tissue microarray was constructed from primary tamor samples from 16 patients, with matched lymph node metastases in 5 cases. Immunohistochemistry was used to evaluate selected biomarkers associated with prostate cancer progression. Standard statistical methodologies were used to compute the distribution of time to progression and overall survival associations between pairs of biomarkers. Hierarchical clustering was done between groups of biomarkers, and we devised new methods to assess homogeneity of biomarker expression. Results: The median interval from diagnosis to salvage surgery was 65 months. The profile of biomarker expression was notable for virtual absence of neuroendocrine features, high CD10, low matrix metalloproteinase (MMP)-9, high E-cadherin expression, and high membranous β-catenin. The mean proliferative index was 12.1 ± 10.1{\%}, and the mean apoptotic index was 3.48 ± 2.22{\%}, and there was a significant correlation between these indices. Expression of the epidermal growth factor receptor was associated with phospho-AKT and proliferative index but inversely associated with phospho-STAT3. Conclusions: The cohort of prostate cancer patients, characterized by locally aggressive disease rather than lethal metastatic progression, was associated with a distinctive biomarker signature. The biomarker profile was, in general, more consistent with low-grade prostate cancer exhibiting local growth rather than metastatic progression. Ongoing studies will establish whether this unique subset of patients can be identified prospectively.",
author = "Assikis, {Vasily J.} and Do, {Kim Anh} and Sijin Wen and Xuemei Wang and Cho, {Jeong Hee} and Shawn Brisbay and Remigio Lopez and Logothetis, {Christopher J.} and Patricia Troncoso and Papandreou, {Christos N.} and McDonnell, {Timothy J.}",
year = "2004",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-04-0275",
language = "English (US)",
volume = "10",
pages = "6770--6778",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential

AU - Assikis, Vasily J.

AU - Do, Kim Anh

AU - Wen, Sijin

AU - Wang, Xuemei

AU - Cho, Jeong Hee

AU - Brisbay, Shawn

AU - Lopez, Remigio

AU - Logothetis, Christopher J.

AU - Troncoso, Patricia

AU - Papandreou, Christos N.

AU - McDonnell, Timothy J.

PY - 2004/10/15

Y1 - 2004/10/15

N2 - Purpose: We have identified a subset of patients exhibiting extended survival with metastases from androgen-independent prostate cancer of which the principal site of progression was the tumor primary. The purpose of this study was to evaluate the expression of selected biomarkers to characterize this subset of prostate cancer patients. Experimental Design: A 105 core tissue microarray was constructed from primary tamor samples from 16 patients, with matched lymph node metastases in 5 cases. Immunohistochemistry was used to evaluate selected biomarkers associated with prostate cancer progression. Standard statistical methodologies were used to compute the distribution of time to progression and overall survival associations between pairs of biomarkers. Hierarchical clustering was done between groups of biomarkers, and we devised new methods to assess homogeneity of biomarker expression. Results: The median interval from diagnosis to salvage surgery was 65 months. The profile of biomarker expression was notable for virtual absence of neuroendocrine features, high CD10, low matrix metalloproteinase (MMP)-9, high E-cadherin expression, and high membranous β-catenin. The mean proliferative index was 12.1 ± 10.1%, and the mean apoptotic index was 3.48 ± 2.22%, and there was a significant correlation between these indices. Expression of the epidermal growth factor receptor was associated with phospho-AKT and proliferative index but inversely associated with phospho-STAT3. Conclusions: The cohort of prostate cancer patients, characterized by locally aggressive disease rather than lethal metastatic progression, was associated with a distinctive biomarker signature. The biomarker profile was, in general, more consistent with low-grade prostate cancer exhibiting local growth rather than metastatic progression. Ongoing studies will establish whether this unique subset of patients can be identified prospectively.

AB - Purpose: We have identified a subset of patients exhibiting extended survival with metastases from androgen-independent prostate cancer of which the principal site of progression was the tumor primary. The purpose of this study was to evaluate the expression of selected biomarkers to characterize this subset of prostate cancer patients. Experimental Design: A 105 core tissue microarray was constructed from primary tamor samples from 16 patients, with matched lymph node metastases in 5 cases. Immunohistochemistry was used to evaluate selected biomarkers associated with prostate cancer progression. Standard statistical methodologies were used to compute the distribution of time to progression and overall survival associations between pairs of biomarkers. Hierarchical clustering was done between groups of biomarkers, and we devised new methods to assess homogeneity of biomarker expression. Results: The median interval from diagnosis to salvage surgery was 65 months. The profile of biomarker expression was notable for virtual absence of neuroendocrine features, high CD10, low matrix metalloproteinase (MMP)-9, high E-cadherin expression, and high membranous β-catenin. The mean proliferative index was 12.1 ± 10.1%, and the mean apoptotic index was 3.48 ± 2.22%, and there was a significant correlation between these indices. Expression of the epidermal growth factor receptor was associated with phospho-AKT and proliferative index but inversely associated with phospho-STAT3. Conclusions: The cohort of prostate cancer patients, characterized by locally aggressive disease rather than lethal metastatic progression, was associated with a distinctive biomarker signature. The biomarker profile was, in general, more consistent with low-grade prostate cancer exhibiting local growth rather than metastatic progression. Ongoing studies will establish whether this unique subset of patients can be identified prospectively.

UR - http://www.scopus.com/inward/record.url?scp=6044267986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044267986&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0275

DO - 10.1158/1078-0432.CCR-04-0275

M3 - Article

C2 - 15501953

AN - SCOPUS:6044267986

VL - 10

SP - 6770

EP - 6778

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -